Article not rated

Vol. 24 - Num. 93

Original Papers

Evolution of meningococcal vaccination in serogroup B: what has changed over 5 years?

María Vázquez Sáncheza, Cristina Genzor Ríosb, David Molina Herranza, M.ª Violeta Fariña Jaraa, Mónica López Camposc, Carmen Puig Garcíac, Carmen Viñas Viamonted, Enrique Llamas Agúndeze

aMIR-Pediatría. Hospital Universitario Miguel Servet. Zaragoza. España.
bEIR Pediatría. Hospital Universitario Miguel Servet. Zaragoza. España.
cPediatra. CS Actur Norte. Zaragoza. España.
dEnfermera de Pediatría. CS Actur Norte. Zaragoza. España.
eInformático. Sector I. Zaragoza. España.

Correspondence: M Vázquez. E-mail:

Reference of this article: Vázquez Sánchez M, Genzor Ríos C, Molina Herranz D, Fariña Jara MV, López Campos M, Puig García C, et al. Evolution of meningococcal vaccination in serogroup B: what has changed over 5 years? Rev Pediatr Aten Primaria. 2022;24:39-46.

Published in Internet: 25-02-2022 - Visits: 1168


Introduction: meningococcal infection by serogroup B can cause invasive meningococcal disease with 20-30% sequelae and up to 10% mortality.

Material and methods: observational, descriptive and retrospective study of serogroup B meningococcus vaccination in the pediatric population of Sector I of Zaragoza from October-2015 to December-2019. Age of primary vaccination, age group at date of first dose (≤3 months, 4-11 months, 12-23 months, 2-9 years, 10-16 years), sex, health center (HC) and number of doses were studied.

Results: 11776 patients were vaccinated, of which 51.6% were male. They had a mean age of initiation of vaccination at 5.0±4.4 years and 2.2±0.6 mean doses received. The distribution of the total vaccinated among HC was varied, with a difference of 17.8% between the HC. with more vaccination and the CS with less vaccination. 0.7% received the first dose in 2015, 23.8% in 2016, 38% in 2017, 26.7% in 2018 and 10.8% in 2019. 12% had ≤3 months at the start of vaccination, 11.5% 4-11 months, 6.7% 12-23 months, 50.4% 2-9 years and 19.5% 10-16 years, with differences in relation to the date of the first dose (p = 0.000). 2017 had a higher incidence of global vaccination (12.2%), although in infants it was higher in 2018 (42.1%) and in the groups of 2-9 years and adolescents in 2017: 15.8% and 5, 4% respectively. The cumulative incidence was 32.5%, being 133.5% in infants.

Conclusions: despite the promising results obtained on the cumulative incidence, we found numerous differences in vaccination between age groups and H.C., which is why systematic and funded meningococcal B vaccination is interesting.


Meningococcal disease Serogroup B meningococcus Vaccination



This article has no comments yet.